{"nctId":"NCT01644890","briefTitle":"A Phase III Study of NK105 in Patients With Breast Cancer","startDateStruct":{"date":"2012-07"},"conditions":["Breast Cancer Nos Metastatic Recurrent"],"count":436,"armGroups":[{"label":"NK105","type":"EXPERIMENTAL","interventionNames":["Drug: NK105"]},{"label":"Paclitaxel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Paclitaxel"]}],"interventions":[{"name":"NK105","otherNames":[]},{"name":"Paclitaxel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent of the patient signed by herself.\n* Histologically confirmed metastatic or recurrent adenocarcinoma of the breast.\n* Aged 20 to 74 at the time of informed consent.\n\nExclusion Criteria:\n\n* Prior systemic chemotherapy with taxane anticancer drugs for metastatic or recurrent breast cancer.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"20 Years","maximumAge":"74 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival","description":"PFS is defined as the period from the day of randomization until the first observation of lesion progression or death from any cause. Disease progression is defined as PD according to RECIST Ver. 1.1.\n\nAssessment period was from the day of randomisation until the first observation of lesion progression or death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":null},{"groupId":"OG001","value":"8.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"OS is defined as the period from the day of randomization until the day of death from any cause.\n\nAssessment period was from the day of randomisation until the first observation of lesion progression or death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":null},{"groupId":"OG001","value":"36.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate","description":"ORR is the proportion of patients who are assessed as complete response or partial response as the best overall response among evaluable patients, according to RECIST Ver.1.1.\n\nAssessment period was from the day of randomisation until the first observation of lesion progression or death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","spread":null},{"groupId":"OG001","value":"39.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":34,"n":214},"commonTop":["Alopecia","Peripheral sensory neuropathy","Neutrophil count decreased","White blood cell count decreased","Nausea"]}}}